Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LAVA-1207 / LAVA Therap
2021-001789-39: LAVA-1207 Open Label study in patients with therapy refractory metastatic castration resistant prostate cancer	Ongoing	1/2	66	Europe	LAVA-1207, NA, Infusion	LAVA Therapeutics N.V., LAVA Therapeutics N.V.	Prostate Cancer, Prostate Cancer, Diseases [C] - Cancer [C04]
KEYNOTE F73, NCT05369000: Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer	Active, not recruiting	1/2	180	Europe, US	LAVA-1207, LAVA-1207 plus Pembrolizumab	Lava Therapeutics, Merck Sharp & Dohme LLC	Metastatic Castration Resistant Prostate Cancer	04/27	04/27